Clinics in Dermatology
Volume 25, Issue 1 , Pages 33-38 , January 2007

Advances in wound dressings

  • Liza G. Ovington, PhD

      Affiliations

    • Corresponding Author InformationTel.: +1 908 218 2392, +1 484 951 2045 (mobile); fax: +1 775 845 9296.

References 

  1. Majno G. The healing hand: man and wound in the ancient world. Cambridge (Mass): Harvard University Press; 1975;
  2. Winter GD. Formation of scab and the rate of epithelialization of superficial wounds in the skin of the young domestic pig. Nature. 1962;193:293–294
  3. Hinnman CD, Maibach HI. Effect of air exposure and occlusion on experimental human skin wounds. Nature. 1963;200:377–378
  4. Nemeth AJ, Eaglstein WH, Taylor JR, et al. Faster healing and less pain in skin biopsy sites treated with an occlusive dressing. Arch Dermatol. 1991;127:1679–1683
  5. Hutchinson JJ. A prospective clinical trial of wound dressings to investigate the rate of infection under occlusion. In: Proceedings: advances in wound management. London, England: MacMillan; 1993;p. 93–96
  6. Ovington LG. Hanging wet-to-dry dressings out to dry. Home Healthc Nurse. 2001;19:477–483
  7. Jones AM, San Miguel L. Are modern wound dressings a clinical and cost-effective alternative to the use of gauze?. J Wound Care. 2006;15:65–69
  8. In:  Motta G editors. WOUNDSOURCE: The Kestrel wound product sourcebook. Bristol, Vermont: Kestrel Health Information Inc; 2005;
  9. Ovington LG. Wound care products: how to choose. Adv Skin Wound Care. 2001;14:259–264
  10. Ovington LG, Peirce B. Wound dressings: form, function, feasibility and facts. In: Krasner , Sibbald , Rodeheaver  editor. Chronic wound care. 3rd ed. Wayne (Pa): Health Management Publications; 2001;
  11. Trengove NJ, Stacey MC, MacAuley S, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 1999;7:442–452
  12. Falanga V. The chronic wound: impaired healing and solutions in the context of wound bed preparation. Blood Cells Dis. 2004;32:88–94
  13. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol. 1993;101:64–68
  14. Cullen B, Smith R, McCulloch E, Silcock D, Morrison L. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen. 2002;10:16–25
  15. Loots MA, Lamme EN, Mekkes JR, Bos JD, Middelkoop E. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non–insulin-dependent diabetes mellitus) show disturbed proliferation. Arch Dermatol Res. 1999;291:93–99
  16. Mendez MV, Stanley A, Park HY, Shon K, Phillips T, Menzoian JO. Fibroblasts cultured from venous ulcers display cellular characteristics of senescence. J Vasc Surg. 1998;28:876–883
  17. Vande Berg JS, Rudolph R, Hollan C, Haywood-Reid PL. Fibroblast senescence in pressure ulcers. Wound Repair Regen. 1998;6:38–49
  18. Raffetto JD, Mendez MV, Marien BJ, et al. Changes in cellular motility and cytoskeletal actin in fibroblasts from patients with chronic venous insufficiency and in neonatal fibroblasts in the presence of chronic wound fluid. J Vasc Surg. 2001;33:1233–1241
  19. Ovington LG. Overview of matrix metalloprotease modulation and growth factor protection in wound healing. Part 1. Ostomy Wound Manage. 2002;48(6 Suppl):3–7
  20. Cullen B, Watt PW, Lundqvist C, et al. The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol. 2002;34:1544–1556
  21. Vachon DJ, Yager DR. Novel sulfonated hydrogel composite with the ability to inhibit proteases and bacterial growth. J Biomed Mater Res A. 2006;76:35–43
  22. Mian M, Beghe F, Mian E. Collagen as a pharmacological approach in wound healing. Int J Tissue React. 1992;14(Suppl):1–9
  23. Taddeucci P, Pianigiani E, Colletta V, et al. An evaluation of Hyalofill-F plus compression bandaging in the treatment of chronic venous ulcers. J Wound Care. 2004;13:202–204
  24. Colletta V, Dioguardi D, Di Lonardo A, Maggio G, Torasso F. A trial to assess the efficacy and tolerability of Hyalofill-F in non-healing venous leg ulcers. J Wound Care. 2003;12:357–360
  25. Steele K, Irwin G, Dowde N. Cadexomer iodine in the management of venous leg ulcers in general practice. Practitioner. 1996;230:63–68
  26. Harcup JW, Saul PA. A study of the effect of cadexomer iodine in the treatment of venous leg ulcers. Br J Clin Pract. 1986;40:360–364
  27. Ormiston MC, et al. Controlled trial of Iodosorb in chronic venous ulcers. Br Med J (Clin Res Ed). 1985;291:308–310
  28. Skog E, Arnesjo B, Troeng T, et al. A randomized trial comparing cadexomer iodine and standard treatment in the outpatient management of chronic venous ulcers. Br J Dermatol. 1983;109:77–83
  29. Apelqvist J, Ragnarson Tennvall G. Cavity foot ulcers in diabetic patients: a comparative study of cadexomer iodine ointment and standard treatment. An economic analysis alongside a clinical trial. Acta Derm Venereol. 1996;76:231–235
  30. Moberg S, Hoffman L, Grennart ML, Holst A. A randomized trial of cadexomer iodine in decubitus ulcers. J Am Geriatr Soc. 1983;31:462–465
  31. Meaume S, Vallet D, Morere MN, Teot L. Evaluation of a silver-releasing hydroalginate dressing in chronic wounds with signs of local infection. J Wound Care. 2005;14:411–419
  32. Naka K, Watarai S, Tana K, et al. Adsorption effect of activated charcoal on enterohemorrhagic Escherichia coli. J Vet Med Sci. 2001;63:281–285
  33. Pegues AS, Sofer SS, McCallum RE, Hinshaw LB. The removal of 14C labeled endotoxin by activated charcoal. Int J Artif Organs. 1979;2:153–158
  34. Du XN, Niu Z, Zhou GZ, Li ZM. Effect of activated charcoal on endotoxin adsorption. Part 1. An in vitro study. Biomater Artif Cells Artif Organs. 1987;15:229–235

PII: S0738-081X(06)00134-9

doi: 10.1016/j.clindermatol.2006.09.003

Clinics in Dermatology
Volume 25, Issue 1 , Pages 33-38 , January 2007

Article Tools